Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	19.46	19.76	23.63	17.11	38.99	18.27
Short-Term Investments	15.29	15.07	20.93	5.07	-	20.28
Cash & Short-Term Investments	34.74	34.83	44.56	22.18	38.99	38.55
Cash Growth	-28.35%	-21.84%	100.90%	-43.11%	1.14%	116.64%
Accounts Receivable	4.68	2.91	5.27	4.59	3.44	2
Other Receivables	-	0.49	0.48	0.36	0.31	0.77
Receivables	4.68	3.4	5.75	4.95	3.75	2.77
Inventory	19.51	21.24	19.05	16.8	17.95	13.08
Prepaid Expenses	-	0.5	0.44	0.77	0.91	0.84
Other Current Assets	1.59	0.11	0.13	0.17	0.07	0.48
Total Current Assets	60.51	60.08	69.93	44.88	61.67	55.72
Property, Plant & Equipment	9.95	10.02	10.88	9.64	9.92	10.41
Long-Term Deferred Tax Assets	2.97	2.86	3.09	-	-	-
Other Long-Term Assets	0.46	0.46	0.53	1.27	2.08	1.8
Total Assets	73.89	73.42	84.43	55.79	73.67	67.93
Accounts Payable	4.12	4.53	4.32	5.86	6.99	7.22
Accrued Expenses	14.87	13.8	13.2	11.6	16.34	13.61
Current Portion of Long-Term Debt	-	-	20.25	-	-	58.51
Current Portion of Leases	1.43	1.5	1.41	1.12	1.21	1.42
Current Income Taxes Payable	3.48	3.48	2.88	0.53	-	-
Current Unearned Revenue	-	-	-	13.18	8.55	5.39
Other Current Liabilities	0.43	2.31	3.48	0.14	0.1	0.32
Total Current Liabilities	24.32	25.62	45.53	32.43	33.18	86.47
Long-Term Debt	-	-	-	28.19	27.89	-
Long-Term Leases	3.81	4.03	4.62	4.17	4.38	4.47
Long-Term Unearned Revenue	-	-	-	-	11.79	1.72
Other Long-Term Liabilities	-	-	-	-	-	0.05
Total Liabilities	28.68	30.21	50.87	66.43	79.7	94.97
Common Stock	0.08	0.08	0.07	0.05	0.05	0.04
Additional Paid-In Capital	427.14	421.53	415.05	379.17	368.85	320.28
Retained Earnings	-382.01	-378.39	-381.55	-389.86	-374.93	-347.35
Shareholders' Equity	45.21	43.21	33.57	-10.64	-6.04	-27.04
Total Liabilities & Equity	73.89	73.42	84.43	55.79	73.67	67.93
Total Debt	5.24	5.53	26.28	33.47	33.47	64.4
Net Cash (Debt)	29.51	29.3	18.28	-11.29	5.52	-25.86
Net Cash Growth	33.42%	60.31%	-	-	-	-
Net Cash Per Share	0.36	0.36	0.22	-0.23	0.12	-0.89
Filing Date Shares Outstanding	79.61	78.03	73.05	57.35	46.32	45.38
Total Common Shares Outstanding	78.13	75.85	72.95	53.79	45.56	34.77
Working Capital	36.19	34.46	24.4	12.45	28.49	-30.75
Book Value Per Share	0.58	0.57	0.46	-0.20	-0.13	-0.78
Tangible Book Value	45.21	43.21	33.57	-10.64	-6.04	-27.04
Tangible Book Value Per Share	0.58	0.57	0.46	-0.20	-0.13	-0.78
Machinery	-	22.42	22.02	21.32	20.96	20.11
Leasehold Improvements	-	17.91	17.64	16.92	16.76	16.66

Updated May 9, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q